CD47 and achalasia-alacrima syndrome: Ultimately, early-phase clinical trials assessing feasibility, safety, and biomarker responses to CD47-targeted therapies in patients with small AAAs will be essential to validate their disease-modifying potential and to transform the management of this currently untreatable condition.